FMP
PTC Therapeutics, Inc.
PTCT
NASDAQ
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
54.5 USD
1.74 (3.19%)
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
1.86B
2.28B
2.45B
2.29B
2.51B
2.74B
3B
3.28B
3.59B
3.92B
-
22.94
7.43
-6.53
9.46
9.34
9.34
9.34
9.34
425.59M
581.86M
598.9M
-598.89M
575.55M
382.08M
417.75M
456.75M
499.4M
546.02M
22.91
25.48
24.41
-26.12
22.93
13.92
13.92
13.92
13.92
318.44M
419.94M
438.46M
-754M
420.32M
204.54M
223.64M
244.52M
267.35M
292.31M
17.14
18.39
17.87
-32.88
16.75
7.45
7.45
7.45
7.45
107.16M
161.92M
160.43M
155.1M
155.23M
177.54M
194.11M
212.23M
232.05M
253.71M
5.77
7.09
6.54
6.76
6.18
6.47
6.47
6.47
6.47
EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income) EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company (1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments), (2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill) (3*) collections of assets (by ignoring depreciation of assets) (4*) different takeover histories (by ignoring amortization often stemming from goodwill)